Bristol-Myers Squibb Co. has plans to build its new biologics facility in the U.S. The company’s board of directors approved a capital expenditure in the amount of $660 million for the construction of a large-scale multi-product bulk biologics manufacturing facility. The facility will be modular in design in order to accommodate future expansion.